Stuart Wood

Stuart Wood is a biotech entrepreneur in mitochondrial drug discovery, with experience spanning early-stage company building and translational R&D. He has worked on platform-driven approaches to identify small-molecule therapeutics. He was CTO of Nanna Therapeutics, focussed on mitochondrial function enhancers to treat rare and neurodegenerative diseases, acquired by Astellas and headed early discovery at Amphista a TPD company focussing on oncology and neuro.